Screener
Iovance Biotherapeutics, Inc. IOVA Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Series A Convertible Preferred stock, $0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of June 30, 2026 and December 31, 2025 | — | — |
| Series B Convertible Preferred stock, $0.001 par value; 11,500,000 shares designated, 1,932,667 shares issued and outstanding as of June 30, 2026 and December 31, 2025 | 2 | 2 |
| Common stock, $0.000041666 par value; 650,000,000 shares authorized, 452,971,016 and 411,938,061 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 19 | 17 |
| Accumulated other comprehensive income | 13,078 | 16,440 |
| Additional paid-in capital | 3,624,836 | 3,457,654 |
| Accumulated deficit | (2,901,890) | (2,775,530) |
| Total Stockholders’ Equity | 736,045 | 698,583 |
| Total Liabilities and Stockholders’ Equity | $915,531 | $913,170 |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s total liabilities & equity?
- Iovance Biotherapeutics, Inc. (IOVA) reported total liabilities & equity of $915.53M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s total liabilities & equity changed year-over-year?
- Iovance Biotherapeutics, Inc.'s total liabilities & equity increased by 0.9% year-over-year, from $907.44M to $915.53M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s total liabilities & equity?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s total liabilities & equity has grown at a 3.5% compound annual growth rate (CAGR), from $768.46M to $913.17M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Iovance Biotherapeutics, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude